Condition: Reversal of Neuromuscular Blockade · Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
The study is being conducted to evaluate the safety and tolerability of HRS-2162 injection in a single dose in healthy subjects, as well as the characteristics of PK/PD
This description comes directly from the study's public registry record.
Yuanyuan Huang · 0518-82342973 · yuanyuan.huang@hengrui.com
Always discuss trial participation with your own doctor first.
| Sichuan Academy of Medical Sciences &Sichuan Provincial People's Hospital | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07195604